ALDX

0.840016.39%
TC

Todd C. Brady

CEO, President & Director

Dr. Todd C. Brady, M.D., Ph.D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. since January 2012. Dr. Brady is a Co-Founder of Phenome Sciences and serves as its Chief Executive Officer. He serves as a Senior Advisor at Solidus Investment Co., Ltd. He served as Principal Financial and Accounting Officer of Aldeyra Therapeutics, Inc. He was an Entrepreneur-In-Residence at Domain Associates, L.L.C since 2013. He joined Domain Associates in 2004 and served as Principal from 2004 to 2013. He served as an Executive Vice President of Strategic Development and Planning at Xanthus Pharmaceuticals. Dr. Brady served as the Head of Business Development and Medical Director at Aderis Pharmaceuticals. While at Xanthus and Aderis, he was a Medical Consultant on numerous pre-clinical programs and eleven clinical programs in Phases I through IV. He was an Associate of CB Health Ventures, L.L.C. and CB Healthcare II, LP. He was a Senior Associate at CB Health Ventures in Boston. He has been a Director of Spring Bank Pharmaceuticals, Inc. since July 28, 2016. He serves as a Director at Aldexa Pharmasceuticals, Asmacure Ltée, Neuron Systems, Inc., NovaDigm Therapeutics, Inc., Sebacia and CardioPolymers, Inc. He serves as Board Observer status at Orqis Medical, Regado Biosciences, Ruxton Pharmaceuticals, IntegenX Inc., Cortria Corporation, Microchip Biotechnologies and Meritage Pharma, Inc. He served as a Director of Oncobiologics, Inc. from September 2014 to October 31, 2017. He served as Board Observer at Celator Pharmaceuticals, Inc. and Esperion Therapeutics, Inc. Dr. Brady had been an Independent Director of Southeast BIO since November 2006 and Cantex Pharmaceuticals, Inc., since August 2006. Dr. Brady had been Independent Director of Evoke Pharma, Inc., since June 2007 until December 15, 2025. He serves as Director of Aldeyra Therapeutics, Inc. since 2005. He served as a Board Observer at Helixis, Inc and Carticept Medical, Inc. He is on the grant review Board for the New Jersey Commission on Science and Technology, the venture capital Advisor to the New Jersey Biotechnology Council Board of Trustees, a Member of the Duke University Graduate School Board of Visitors, an Advisor to the Translational Science Institute at Wake Forest University and the University of Virgina Coulter Translational Research Advisory Board. He received an M.D. from Duke University Medical School in 1999 and a Ph.D. in Pathology and Integrated Toxicology from the Duke University Graduate School in 1998, while working on the pre-clinical development of catalytic anti-inflammatory compounds. He also received an A.B. in Philosophy and Psychology from Dartmouth College in 1993.

Positions